Dr Neal Shore joins Clarity’s Clinical Advisory Board
Sydney, Australia 26 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity’s Clinical Advisory Board (CAB). Dr Shore MD, FACS is the Chief Medical Officer of Urology/Surgical Oncology at GenesisCare, US and…